A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS
Cell Stem Cell · 2024-01 · 31 (1) · 71-88.e8
DOI: 10.1016/j.stem.2023.11.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2024-01. Verfasst von Xiaohua Duan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
KRAS mutations, mainly G12D and G12V, are found in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases. The success of drugs targeting KRASG12C suggests the potential for drugs specifically targeting these alternative PDAC-associated KRAS mutations. Here, we report a high-throughput drug-screening platform using a series of isogenic murine pancreatic organoids that are wild type (WT) or contain common PDAC driver mutations, representing both classical and basal PDAC phenotypes. We screened over 6,000 compounds and identified perhexiline maleate, which can inhibit the growth and induce cell death of pancreatic organoids carrying the KrasG12D mutation both in vitro and in vivo and primary human PDAC organoids. scRNA-seq analysis suggests that the cholesterol synthesis pathway is upregulated specifically in the KRAS mutant organoids, including the key cholesterol synthesis regulator SREBP2. Perhexiline maleate decreases SREBP2 expression levels and reverses the KRAS mutant-induced upregulation of the cholesterol synthesis pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Center for Genomic Health, 1300 York Ave., New York, NY 10065, USA.
- Genomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10065, USA.
- Department of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Key Laboratory of Pesticide and Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal Universi…
- Department of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA.
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
- Department of Surgery, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- Irma T. Hirschl Trust
- Weill Cornell Medicine
- Department of Surgery
Zitieren
APA
Duan, X., Zhang, T., Feng, L., de Silva, N., Greenspun, B., Wang, X., Moyer, J., Martin, M. L., Chandwani, R., Elemento, O., Leach, S. D., Evans, T., Chen, S., & Pan, F. C. (2024). A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell Stem Cell, 31(1), 71-88.e8. https://doi.org/10.1016/j.stem.2023.11.011
Vancouver
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, et al. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell Stem Cell. 2024;31(1):71-88.e8. doi:10.1016/j.stem.2023.11.011
BibTeX
@article{Duan2024,
author = {Duan, Xiaohua and Zhang, Tuo and Feng, Lingling and de Silva, Neranjan and Greenspun, Benjamin and Wang, Xing and Moyer, Jenna and Martin, M Laura and Chandwani, Rohit and Elemento, Olivier and Leach, Steven D and Evans, Todd and Chen, Shuibing and Pan, Fong Cheng},
title = {A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS},
journal = {Cell Stem Cell},
year = {2024},
volume = {31},
number = {1},
pages = {71--88.e8},
doi = {10.1016/j.stem.2023.11.011}
}
EUVIMED